Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clofutriben - Sparrow pharmaceuticals

Next Previous
Drug Profile

Clofutriben - Sparrow pharmaceuticals

Alternative Names: SPI-62

Latest Information Update: 26 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sparrow Pharmaceuticals
  • Class Antirheumatics; Obesity therapies; Small molecules
  • Mechanism of Action 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cushing syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adrenal gland disorders; Cushing syndrome; Polymyalgia rheumatica
  • No development reported Diabetic neuropathies; Obesity

Most Recent Events

  • 16 May 2025 Sparrow Pharmaceuticals terminates a phase I trial for Polymyalgia Rheumatica (Combination therapy) in Germany due to lack of enrollment (NCT06281236)
  • 25 Apr 2025 Sparrow Pharmaceuticals completes a phase-II clinical trials in Polymyalgia rheumatica (Combination therapy) in Germany and Poland (PO) (NCT05436652) (EudraCT2022-000299-20)
  • 26 Feb 2025 Sparrow Pharmaceuticals terminates a phase II ACSPIRE trial for Cushing syndrome due to unclear benefit for this patient population in USA, Romania and United Kingdom (NCT05436639)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top